American management, oversee food safety and medicines (FDA USA) approved clinical trials of psilocybin, a beneficial effect on patients who are resistant to other methods the treatment of depression. Resolution on the full-scale study in the framework of the above issues were biomedical company Compass Pathways (base date of 2016, London).
As stated in the press release, these tests were previously approved by the regulatory authorities in Canada, the United Kingdom, the Netherlands. And all will begin with the United Kingdom. Next, as soon as will be received permits supervisory authorities, to be joined by English patients from other states.
The tests will take place in 12 or 15 research centers, and will take part in them 216 Americans and Europeans suffering from resistant depression.
In the second stage of the study will be subjected to a detailed analysis of the effect achieved as a result of receiving psilocybin on the background of the professional psychological support. If it turns out that the combination works, the experiment enters its third stage, where it will be possible to compare how the new method is more effective (or ineffective) previously used or placebo.
What is an alkaloid psilocybin and why so many hopes are pinned on him? This active substance derived from hallucinogenic fungi of the genus Psilocybe. Scientific studies have confirmed the effect of this substance on patients with depression. These experiments were made in the 50-60s of the last century, but in 70th ceased since studied hallucinogenic drugs have been recognized and are forbidden to use. And now, in the twenty-first century, interest in general to psychotropics and psilocybin in particular returns.
Want to know more about medicine? Do not forget to support our channel in service Yandex. Zen Like and subscription. It motivates us to publish more interesting materials. Also, you can quickly learn about new publications.
